Company Projected Revenue: Milestone Pharmaceuticals Inc (MIST)

Official company branding of milestonepharma.com (MIST)

Milestone Pharmaceuticals (MIST) is developing a high-margin tachycardia treatment with minimal production costs. The company is establishing an emergency care system by integrating the drug into patients' daily lives, although it currently faces a liquidity shortage due to launch expenses. The company's projected sales volume exhibits a sideways trend, with the indicator standing at 0.00, highlighting the gap between the share price and its potential.

MIST - milestonepharma.com Company Expected Sales Volume over the range 07/04/2022 - 11/14/2026

Milestone Pharma - analytical breakdowns and key metrics (MIST)

- stock value and consensus price forecast:
Price Chart Milestone Pharmaceuticals Inc|MIST - Average Forecast Price
- company stock exchange capitalization indicators:
Market Value Milestone Pharmaceuticals Inc.|MIST - Business Value
- balance sheet equity data:
Book Value per Share Milestone Pharmaceuticals|MIST - Total Stockholders' Equity|Market Cap to Net Assets Ratio milestonepharma.com|MIST - Aggregate Asset Value
- business debt structure and liquidity details:
Debt to Equity Milestone Pharmaceuticals|MIST - Long-Term Liabilities to Equity|Short-Term Debt to Capital Milestone Pharmaceuticals|MIST - Aggregate Debt Obligations|Debts to Book Capitalization Milestone Pharma|MIST - Company Long-Term Debts|Company Short-Term Debt Milestone Pharmaceuticals|Quick Liquidity milestonepharma.com
- earnings and market ratios statistics:
MIST - Net Income|Projected Future Earnings Milestone Pharmaceuticals|MIST - P/E Multiple|Forward P/E Multiple Milestone Pharmaceuticals Inc|MIST - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Milestone Pharmaceuticals, Inc.|MIST - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months Milestone Pharmaceuticals|MIST - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months milestonepharma.com|MIST - Net earnings per one share growth for the current year|Earnings growth forecast for next year Milestone Pharmaceuticals
- sales and revenue data:
MIST - Company Gross Revenue|Projected Sales Volume Milestone Pharmaceuticals, Inc.|MIST - Market Cap to Revenue|Forward P/S Multiple Milestone Pharma
Fundamental valuation:milestonepharma.com
Signature product of Milestone Pharmaceuticals, Inc.

This indicator measures expected revenue as the basis for market value, allowing investors to assess the gap between the asset's current price and its future scale. The trend in projected sales for Milestone Pharmaceuticals (MIST) reflects the company's critical dependence on its commercial partner while awaiting regulatory drug approval in the absence of M&A transactions.

Analysis of competing companies

Company Projected Revenue Regeneron (REGN)|Company Future Sales Volume iRhythm Technologies Inc IRTC|Company Projected Revenue Lantheus Corp LNTH|Mineralys Corp (MLYS) - Company Expected Sales Volume|HTFL: Company Future Sales Volume|Company Expected Sales Volume Kestra Medical Technologies|ESPR (Esperion Therapeutics) - Company Future Sales Volume|Amarin Corporation - Company Future Revenue|AVR (anteristech.com) - Projected Sales Volume|TNYA: Company Future Revenue|Company Projected Revenue CVRx, Inc. (CVRX)|CRDL (Cardiol Therapeutics Inc.) - Company Future Revenue|Projected Sales Volume BEAT (HeartBeam Inc)|Tenax Therapeutics, Inc (TENX) - Company Expected Sales Volume|ADGM - Company Projected Revenue|Company Future Sales BioCardia, Inc BCDA|catheterprecision.com (VTAK) - Company Projected Revenue|ARCA Biopharma Inc (ABIO) - Projected Sales Volume|Company Projected Revenue Acasti Pharma Inc.|Company Expected Sales Volume Aerovate AVTE|Projected Sales Volume VERV|Projected Sales Volume Windtree (WINT)